Resource Type

Journal Article 679

Year

2024 1

2023 39

2022 54

2021 65

2020 40

2019 60

2018 47

2017 53

2016 30

2015 35

2014 32

2013 32

2012 32

2011 23

2010 18

2009 39

2008 15

2007 21

2006 4

2005 2

open ︾

Keywords

fuel cell 13

immunotherapy 9

targeted therapy 8

cancer 7

cancer therapy 7

hepatocellular carcinoma 6

solar cell 6

therapy 6

COVID-19 5

SARS-CoV-2 5

gene therapy 5

hematopoietic stem cell transplantation 5

hydrogen energy 5

lung cancer 5

stem cell 5

cell proliferation 4

control 4

immune checkpoint inhibitor 4

microbial fuel cell 4

open ︾

Search scope:

排序： Display mode:

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: achieved complete remission after receiving the CD19 CAR-T cell therapy.cell therapy.Nonetheless, the CAR-T therapy was usually associated with potentially lethal adverse effects, such asTherefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy withthe toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

Yongping Zhang, Xingying Zhang, Chen Cheng, Wei Mu, Xiaojuan Liu, Na Li, Xiaofei Wei, Xiang Liu, Changqing Xia, Haoyi Wang

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 554-562 doi: 10.1007/s11684-017-0543-6

Abstract: The immunosuppressive nature of tumor microenvironment is considered one of the key factors limiting CAR-TWe successfully generated LAG-3 knockout T and CAR-T cells with high efficiency using LAG-3 knockout CAR-T cells displayed robust antigen-specific antitumor activity incell culture and in murine xenograft model, which is comparable to standard CAR-T cells.Our study demonstrates an efficient approach to silence immune checkpoint in CAR-T cells via gene editing

Keywords： CAR-T     CRISPR-Cas9     LAG-3    

HTML PDF Collect

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues Review

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Engineering 2019, Volume 5, Issue 1,   Pages 122-131 doi: 10.1016/j.eng.2018.12.003

Abstract:

Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancerCAR-T cells are genetically modified T cells that can specifically recognize tumor specific antigensAt present, exciting results are being achieved in clinical applications of CAR-T cells for patientsThe research and development of CAR-T cells for various targets and for the treatment of solid tumorscell products based on their product characteristics and on relevant guidelines for gene and cell therapy

Keywords： Chimeric antigen receptor T cells     Quality control     Nonclinical research     Safety     Efficacy     Clinical    

HTML PDF Collect

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

Frontiers of Medicine 2019, Volume 13, Issue 5,   Pages 610-617 doi: 10.1007/s11684-019-0714-8

Abstract: Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely usedDespite its remarkable clinical effects, this therapy has side effects that cannot be underestimated.refractory multiple myeloma and three patients with acute lymphocytic leukemia who suffered CRS during CAR-T

Keywords： chimeric antigen receptor T cell     cytokine release syndrome     tocilizumab    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: in outcome will need to rely more heavily on molecular therapeutic as well as immuno- and cellular-therapyand other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cellprecursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2targetable genetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-Tcell therapy for B-ALL, and daratumumab and nelarabine for T-ALL.

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell therapy    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of T, for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL).Ten heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatmentNeurotoxicity or other dose-limiting toxicities was not observed in any dose cohort of C-CAR011 therapy

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalIn this review, through a representative case study, we summarize the current experience of CAR T-celltherapy, the management of common side effects, the causative mechanisms of therapy resistance, andnew strategies to improve the efficacy of CAR T-cell therapy.

Keywords： CAR T cells     hematological malignancies     review    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatmentHowever, several clinical trials of solid tumor CAR-T therapies were prematurely terminated, or theyaberrantly glycosylated glycoforms of tumor-associated antigens can also minimize the off-tumor effects of CAR-TTn, T, and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,discuss how underglycosylated antigens emerge and then detail the latest advances in the development of CAR-T-based

Keywords： chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation     O-glycans     adoptive celltherapy    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAllogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemiaAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 3-11 doi: 10.1007/s11684-019-0684-x

Abstract: The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltratingCurrently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughsThe clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited.Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe sideIn this review, we summarized the current application of ACT, the challenges encountered by CAR-T technology

Keywords： adoptive cell transfer therapy     hepatocellular carcinoma     T cell     chimeric antigen receptor     immunotherapy    

HTML PDF Collect

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Review

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Engineering 2022, Volume 10, Issue 3,   Pages 30-43 doi: 10.1016/j.eng.2021.10.018

Abstract: ) are a breakthrough in genetic engineering that have revolutionized the field of adoptive cellular therapyto a predefined target by the inclusion of an antigen-specific binding region within the synthetic CARIn contrast to conventional T cells (Tconvs), regulatory T cells (Tregs) play a major role in suppressingCAR expression within Tregs has been proposed as a therapy for autoimmune and inflammatory diseases,This review examines the rationale behind the development of CAR-Tregs, their significance for human

Keywords： Chimeric antigen receptors     T cell     Treg     Alloimmunity     Bioengineering     Transplant     Autoimmunity    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallyT-cell therapy.CAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

Engineered T Cell Therapies from a Drug Development Viewpoint Review

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Engineering 2019, Volume 5, Issue 1,   Pages 140-149 doi: 10.1016/j.eng.2018.11.010

Abstract: Recent advances in cellular therapy have demonstrated that this platform has the potential to give patientsFor example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowingThis article reviews the use of biomarker-based assays to guide the optimization of CAR constructs, preclinicalAdvanced technologies and computational tools that enable the discovery of optimal targets, novel CARWe believe that the success of CART19 will lead to the development of other engineered T cell therapies

Keywords： Engineered T cell therapies     Chimeric antigen receptor     Drug development process     Biomarkers     CAR19    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellcells, leading to CAR-T cell therapy failure and disease progression in DLBCL.Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansioncell therapy.

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 726-745 doi: 10.1007/s11684-020-0746-0

Abstract: Chimeric antigen receptor (CAR) T cells have been indicated effective in treating B cell acute lymphoblasticHowever, CAR T cells have achieved minimal success against solid malignancies because of the additionalIn this review, we focus on the recent advances in the engineering of CAR T cell therapies to restoreT cell therapy.the anti-tumor outcomes of CAR T cell therapies in solid tumors.

Keywords： CAR T cells     immunoregulatory molecules     endogenous immune response     solid malignancies    

HTML PDF Collect

Title Author Date Type Operation

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

Yongping Zhang, Xingying Zhang, Chen Cheng, Wei Mu, Xiaojuan Liu, Na Li, Xiaofei Wei, Xiang Liu, Changqing Xia, Haoyi Wang

Journal Article

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Journal Article

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Journal Article

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

Engineered T Cell Therapies from a Drug Development Viewpoint

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Journal Article

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Journal Article